An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38low blasts

Research output: Contribution to journalArticlepeer-review

Standard

An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients : blood frequency of CD34+ CD38low blasts. / Khan, Naeem; Freeman, Sylvie; Virgo, Paul; Couzens, S.; Richardson, Peter; Thomas, Ian; Grech, Angela; Vyas, Paresh; Grimwade, David; Russell, N. H.; Burnett, Alan K; Hills, Robert.

In: British Journal of Haematology, Vol. 170, No. 1, 07.2015, p. 80–84.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Khan, Naeem ; Freeman, Sylvie ; Virgo, Paul ; Couzens, S. ; Richardson, Peter ; Thomas, Ian ; Grech, Angela ; Vyas, Paresh ; Grimwade, David ; Russell, N. H. ; Burnett, Alan K ; Hills, Robert. / An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients : blood frequency of CD34+ CD38low blasts. In: British Journal of Haematology. 2015 ; Vol. 170, No. 1. pp. 80–84.

Bibtex

@article{f263cfcec019469d8bc74865c55adfd2,
title = "An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38low blasts",
abstract = "Many older patients with acute myeloid leukaemia (AML) that receive standard intensive chemotherapy fail to achieve complete remission (CR). Upfront identification of patients unlikely to benefit from standard induction chemotherapy would be important for exploration of novel therapies. This study evaluated if a flow cytometric assay measuring pre-treatment CD34+ CD38low blast frequency could predict therapeutic-resistance in 736 AML patients entered into the UK National Cancer Research Institute AML16 trial. High peripheral blood CD34+ CD38low blast frequency (>7% of leucocytes), present in 18% of assessable patients, conferred significantly reduced CR rates (38% vs. 76%, P < 0·0001) and poor survival, and was independently prognostic for all endpoints of treatment resistance by multivariate analysis.",
keywords = "Acute myeloid leukaemia, older patients, flow cytometry, Prognostic",
author = "Naeem Khan and Sylvie Freeman and Paul Virgo and S. Couzens and Peter Richardson and Ian Thomas and Angela Grech and Paresh Vyas and David Grimwade and Russell, {N. H.} and Burnett, {Alan K} and Robert Hills",
year = "2015",
month = jul,
doi = "10.1111/bjh.13398",
language = "English",
volume = "170",
pages = "80–84",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients

T2 - blood frequency of CD34+ CD38low blasts

AU - Khan, Naeem

AU - Freeman, Sylvie

AU - Virgo, Paul

AU - Couzens, S.

AU - Richardson, Peter

AU - Thomas, Ian

AU - Grech, Angela

AU - Vyas, Paresh

AU - Grimwade, David

AU - Russell, N. H.

AU - Burnett, Alan K

AU - Hills, Robert

PY - 2015/7

Y1 - 2015/7

N2 - Many older patients with acute myeloid leukaemia (AML) that receive standard intensive chemotherapy fail to achieve complete remission (CR). Upfront identification of patients unlikely to benefit from standard induction chemotherapy would be important for exploration of novel therapies. This study evaluated if a flow cytometric assay measuring pre-treatment CD34+ CD38low blast frequency could predict therapeutic-resistance in 736 AML patients entered into the UK National Cancer Research Institute AML16 trial. High peripheral blood CD34+ CD38low blast frequency (>7% of leucocytes), present in 18% of assessable patients, conferred significantly reduced CR rates (38% vs. 76%, P < 0·0001) and poor survival, and was independently prognostic for all endpoints of treatment resistance by multivariate analysis.

AB - Many older patients with acute myeloid leukaemia (AML) that receive standard intensive chemotherapy fail to achieve complete remission (CR). Upfront identification of patients unlikely to benefit from standard induction chemotherapy would be important for exploration of novel therapies. This study evaluated if a flow cytometric assay measuring pre-treatment CD34+ CD38low blast frequency could predict therapeutic-resistance in 736 AML patients entered into the UK National Cancer Research Institute AML16 trial. High peripheral blood CD34+ CD38low blast frequency (>7% of leucocytes), present in 18% of assessable patients, conferred significantly reduced CR rates (38% vs. 76%, P < 0·0001) and poor survival, and was independently prognostic for all endpoints of treatment resistance by multivariate analysis.

KW - Acute myeloid leukaemia

KW - older patients

KW - flow cytometry

KW - Prognostic

U2 - 10.1111/bjh.13398

DO - 10.1111/bjh.13398

M3 - Article

VL - 170

SP - 80

EP - 84

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -